Hormone replacement therapy, the menopause, and breast cancer

Breast Cancer: Prognosis, Treatment, and Prevention

Volumn , Issue , 2002, Pages 373-403

  Marsden, Jo ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85056964136     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (181)

1. Anderson TJ. Effects on breast tissue of exogenous estrogen and progestogens. Acta Obstet Gynaecol Scand 1986; 134(Suppl): 9-16.
2. Archer DF, Pickar JH, Bottiglion F. Bleediing patterns on postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with mederoxyprogesterone acetate. Obstet Gynaecol 1994; 83: 686-692.
3. Armstrong BK. Oestrogen therapy after the menopause: boon or bane? Med J Aust 1988; 148: 213-214.
4. Bachmann GA. The clinical platform for the 17P-estradiol vaginal releasing ring. Am J Obstet Gynaecol 1998; 178: S257-260.
5. Barclay M, Cogin GF, Escher GC, Kaufman RJ, Kidder ED, Peterman ML. Human plasma lipoproteins. I. In normal women and in women with advanced carcinoma of the breast. Cancer 1955; 8: 253-260.
6. Barclay M, Calathes N, DiLorenzo JC, Helper A, Kaufman RJ. The relation between plasma lipoproteins and breast carcinoma: Effect of degrees of breast disease on plasma lipoproteins and the possible role of lipid metabolic aberrations. Cancer 1959; 11: 1163-1170.
7. Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA 1991; 265: 1861-1867.
8. Barton DL, Loprinzi CL, Quella SK, Slaon JA, Veede MH, Egner JR, Fidler P, Stella PJ, Swan DK, Vaught NL, Novotny P. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol 1998; 16: 495-500.
9. BASO Breast Speciality Group. The British Association of Surgical Oncology Guidelines for surgeons in the management of symptomatic breast disease in the UK (1998 revision). Eur J Surg Oncol 1998; 24: 464-476.
10. Baum M, Rutgers EE on behalf of the ZIPP trial. Zoladex and tamoxifen as adjuvant therapy in premenopausal breast cancer: a randomised trial by the Cancer Research Campaign (CRC) Breast Cancer Trials Group, the Stockholm Breast Cancer Study Group, the South-East Sweden Breast Cancer Group and the Gruppa Interdisciplinara Valurazlone Interventl in Oncolog-igia (GIVIO) (abstr 070). Abtracts of the 6th Nottingham International Breast Cancer Conference. The Breast 1999; 8: 233.
11. Beatson GT. On the treatment of inoperable carcinoma of the mamma: Suggestions for a new method of treatment, with illustrative cases. Lancet 1896; 2: 104-107.
12. Berkqvist L, Adami HO, Persson I, Bergstrom R, Krusemo UB. Prognosis after breast cancer diagnosis in women exposed to oestrogen and oestrogen-progestogen replacement therapy. Am J Epidemol 1992; 130: 221-228.
13. Berrino F, Muti P, Micheli A, Bolelle G, Krogh V, Sciajno R, Pisani P, Panico S, Secreto G. Serum sex hormone levels after menopause and subsequent breast cancer. J Natl Cancer Inst 1996; 88: 291-296.
14. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996; 14: 1718-1729.
15. Bisgaier CL, Pape ME. High density lipoprotein: Are elevated levels desirable and achievable? Curr Pharm Design 1998; 4: 53-70.
16. Bluming AZ, Waisman JR, Dosik GM, Olsen GA, Rosenbloom BE, McAndrew P, Terpenning M, Decker RW, Klein JH, Van Scoy Mosher M, Green LM, Masterson M, Beard DB. Vogel CL, While AG, Schain W. Hormone replacement therapy in women with previously treated primary breast cancer (abstr 471). Proceedings of the (35th) Annual Meeting of the American Society of Clinical Oncology 1999; 19.
17. Bonadonna G, Valagussa P. Adjuvant systemic therapy for resectable breast cancer. J Clin Oncol 1985; 3: 259-275.
18. Bonnier P, Romain S, Giacalone PL, Laffargue F, Martin PM, Piana L. Clinical and biologic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy. Obstet Gynaecol 1995; 85: 11-17.
19. Bonnier P. Bessenay F, Sasco AJ, Beedassy B, Lejeune C, Romain S, Charpin C, Piana L, Martin PM. Impact of menopausal hormone-replacement therapy on clinical and laboratory characteristics of breast cancer. Int J Cancer 1998; 79: 278-282.
20. Byrne C, Schairer C, Wolfe J, Parekh N, Salane M, Brinton LA, Hoover R, Hale R. Mammographic features and breast cancer risk: Effects with time, age and menopausal status. J Natl Cancer Inst 1995; 87: 1622-1629.
21. Campagnoli C, Biglia N, Peris C, Sismondi P. Potential impact on breast cancer risk of circulating insulin-like growth factor I modifications induced by oral HRT in menopause. Gynecol Endocrinol 1995; 9: 67-74.
22. Canney PA, Hatton MQF. The prevalence of menopausal symptoms in patients treated for breast cancer. Clin Oncol 1994; 6: 297-299.
23. Carpenter JS, Andykowski MA, Cordova M, Cunningham L, Studts J, McGrath P, Kenady D, Sloan D, Munn R. Hot flashes in postmenopausal women treated for breast carcinoma. Cancer1998; 82: 1682-1691.
24. Carter AC, Sedransk N. Kelley RM, Ansfield FJ, Ravdin RG, Talley RW, Potter NR. Diethylstilbes-trol: Recommended dosages for different categories of breast cancer patients. JAMA 1977; 237: 2079-2085.
25. Catherino WH, Jeng MH, Jordan VC. Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism. Br J Cancer 1993; 67: 945-952.
26. Cauley JA, Lucas FL, Kuller LH, Stone K, Browner W, Cummings SR. Elevated serum estradiol and testosterone concentrations are assocaited with a high risk for breast cancer. Ann Intern Med 1999a; 130: 270-277.
27. Cauley J, Krueger K, Eckert S, Muchmore D, Taylor Y, Scott T. Raloxifene reduces breast cancer risk in postmenopausal women with osteoporosis: 40-month data from the MORE trial (abstr 328). Proceedings of the Annual Meeting (35th) of the American Society of Clinical Oncology1999b; 18.
28. Chang J, Powles TJ, Ashley SE, Gregory K, Tidy VA, Treleaven JG, Singh R. The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised, controlled tamoxifen prevention study. Ann Oncol 1996; 7: 671-675.
29. Chang J, Powles TJ, Ashley SE, Iveson T, Gregoary RK, Dowsett M. Variation in endometrial thickening in women with amenorrhoea. Br Cancer Res Treat 1998; 48: 81-85.
30. Cheblowski RT, Collyar DE, Somerfield MR, Pfister D for the American Society of Clinical Oncology Working Group on Breast Cancer Risk Reduction Strategies. Tamoxifen and Raloxifene. J Clin Oncol 1999; 17: 1939-1955.
31. Chenoy R, Hussain S, Tayob V, O’Brien PMS, Moss MY, Morse PF. Effect of oral gamolenic acid for evening primrose oil on menopausal flushing. BMJ 1992; 308: 501-503.
32. Clarke CL, Sutherland R. Progestin regulation of cellular proliferation. Endocr Rev 1990; 11: 266301.
33. Cobleigh MA, Bines J, Harris D. Amenorrhoea following adjuvant chemotherapy for breast cancer (abstr 55). Proceedings from the (31st) Annual Meeting of the American Society of Clinical Oncology 1995; 14.
34. Cobleigh MA, Norlock FE, Oleske DM, Starr A. Hormone replacement therapy and high S phase in breast cancer. JAMA 1999; 281: 1528-1530.
35. Colditz GA, Egan KM, Stampfer MJ. Hormone replacement therapy and risk of breast cancer: Results from epidemiological studies. Am J Obs Gynecol 1993; 168: 1473-1480.
36. Colditz GA, Rosner B for the Nurses’ Health Study Research Group, Use of estrogen plus progestin is associated with greater increase in breast cancer risk than estrogen alone. Am J Epidemiol1998; 147(Suppl): 64S.
37. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: Collaborative reanalysis of individual data on 53,297 women with and 100.239 women without breast cancer from 54 epidemiological studies, Lancet 1996; 347: 1713-1727.
38. Collaborative Group on Hormonal Factors for Breast Cancer. Breast cancer and hormone replacement therapy: Collaborative reanalysis from 51 individual epidemiological studies. Lancet 1997; 350: 1047-1060.
39. Consensus Statement. Treatment of estrogen deficiency symptoms in women surviving breast cancer. J Clin Endocrinol Metab 1998; 83: 1993-2000.
40. Cortes-Prieto J. Coagulation and fibrinolysis in post-menopausal women treated with Org OD14. Maturitas 1987; (Suppl 1): 67-72.
41. Couzi RJ, Helzlsouer KJ, Fetting JH. Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy. J Clin Oncol 1995; 13: 2737-2744.
42. Cowan LD. Gordis L, Tonascia JA, Jones GS. Breast cancer incidence in women with progesterone deficiency. Am J Epidemol 1981; 114: 209-217.
43. Criqui MH, Suarez L, Barrett-Connor EL, McPhillips J, Wingard DL, Garland C. Postmenopausal estrogen use and mortality. Am J Epidemol 1988; 128: 606-614.
44. Dao TL, Sinha DK, Memto T, Patel J. Effect of oestrogen and progesterone on cellular replication of human breast tumours. Cancer Res 1982; 42: 359-362.
45. Darling GM, Johns JA, McCloud PI, Davis SR. Estrogen and progestin compared with simastatin for hypercholesterolaemia in postmenopausal women. N Engl J Med 1997; 337: 595-601.
46. Davidson NE, O’Neill A, Vukov A, Osborne CK, Martino S, White D, Abeloff MD. Effect of chemohormonal therapy in premenopausal, node-positive, receptor-positive breast cancer and Eastern Cooperative Oncology Group Phase III Intergroup Trial (E5188, INT-0101) (abstr 069). Abstracts of the 6th Nottingham International Breast Cancer Conference, The Breast1999; 8: 232.
47. Day R, Ganz PA, Costantino JP, Cronin WM, Wickerham L, Fisher B. Health-related quality of life and tamoxifen in breast cancer prevention: a report form the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol 1999; 17: 2659-2669.
48. Decensi A. Robertson C, Rotmensz N, Severi G, Maisonneuve P, Sacchini V, Boyle P, Costat A, Veronesi U. Effect of tamoxifen and transdermal hormone replacement therapy on cardiovascular risk factors in a prevention trial. Br J Cancer 1998; 78: 572-578.
49. Decker D, Cox T, Burdakin J, Jaiyesimi I, Pettinga J, Benitez P. Hormone replacement therapy (HRT) in breast cancer survivors (abstr 209). Proceedings of the (32nd) Annual Meeting of the American Society of Clinical Oncology 1996; 15.
50. DeFriend DJ, Howell A, Micholson RI, Anderson E, Dowsett M, Mansel RE, Blamey RW, Bundred NJ, Robertson JF, Saunders C, Baum M, Walton P, Sutcliffe F, Wakeling AE. Investigation of a pure new antioestrogen (ICI 182780) in women with primary breast cancer. Cancer Res1994; 54: 408-414.
51. Dhodapkar MV, Ingle JN, Ahmann DL. Estrogen replacement therapy withdrawal and regression of metastatic breast cancer. Cancer 1995; 75: 43-46.
52. DiSaia PJ, Odicino F, Grosen EA, Cowan B, Peconelli S, Wile AG. Hormone replacement therapy in breast cancer. Lancet 1993; 342: 1232.
53. Downs JR, Clearfield M, Weis SW, Whitney E, Sharpiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM for the AFCAPS/TexCAPS Research Group, Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 1998; 279: 1615-1622.
54. Dupont WD, Page D, Rogers LW, Parl FF. Influence of exogenous estrogens, proliferative breast disease and other variables on breast cancer risk. Cancer 1989; 63: 948-957.
55. Dupont WD, Page DL, Parl FF, Plummer WD, Schuyler PA, Kasami M, Jensen RA. Estrogen replacement therapy in women with a history of proliferative breast disease. Cancer 1999; 85: 1277-1283.
56. Early Breast Cancer Trialists’ Collaborative Group. Ovarian ablation in early breast cancer: Overview of the randomised trials. Lancet 1996; 348: 1189-1196.
57. Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: An overview of randomised trials. Lancet 1998a; 351: 1451-1467.
58. Early Breast Cancer Trialists’ Collaborative Group. Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 1998b; 352: 930-942.
59. Eden JA, Bush T, Nand S, Wren BG. A case-controlled study of combined continuous oestrogen-progestogen replacement therapy amongst women with a personal history of breast cancer. Menopause-J N Am Menopause Soc 1995; 2: 67-72.
60. Ellerington MC, Whitcroft SIJ, Whitehead MI. Developments in therapy. Br Med Bull 1992; 48: 401-425.
61. Espie M, Gorins A, Perret F, Tournant B, Lipszyg J, Nowak H, Bedairia N, Marty M. Hormone replacement therapy (HRT) in patients treated for breast cancer: Analysis of a cohort of 120 patients (abstr 2262). Proceedings of the (35th) Annual Meeting of the American Society of Clinical Oncology 1999; 19.
62. Fabian CJ, Kimler BF, McKittrick R, Park CH, Lin F, Krishnan L, et al. Recruitment with high physiological doses of estradiol preceding chemotherapy: Flow cytometric and therapeutic results in women with locally advanced breast cancer-A Southwest Oncology Group Study. Cancer Res 1994; 54: 5357-5362.
63. Fallowfield LJ, Leaity SK, Howell A, Benson S, Cella D. Assessment of quality of life in women undergoing hormonal therapy for breast cancer; validation of an endocrine symptom subscale for the FACT-B. Breast Cancer Res Treat 1999; 55: 89-199.
64. Fisher B, Constatino JP, Wickerham DI, Redmond CK, Kavanah M, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L. Wolmark N and other National Surgical Adjuvant Breast and Bowel Project Investigators. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowle Project P-1 Study. J Natl Cancer Inst 1998; 90: 1371-1388.
65. Foidart JM, Colin C, Denoo X, Desreux J, Béliard A, Fournier S, de Lignières B. Estradiol and progesterone regulate the proliferation of human breast epithelial cells. Fertil Steril 1998; 69: 963-969.
66. Folsom AR, Mink PJ, Sellers TA, Hong CP, Zheing W, Potter JD. Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women. Am J Public Health 1995; 85: 1128-1132.
67. Fowble B, Hanlon A, Freedman G, Patchefsky A, Kessler H, Nicolaou N, Hoffman J, Sigurdson E, Boraas M, Goldstein L. Postmenopausal hormone replacement therapy: Effect on diagnosis and outcome in early-stage invasive breast cancer treated with conservative surgery and radiation. J Clin Oncol 1999; 17: 1680-1688.
68. Gambrell DR. Proposal to decrease the risk and improve the prognosis in breast cancer. Am J Obstet Gynaecol 1984; 150: 119-128.
69. Ganger K. Cust M, Whitehead MI. Symptoms of oestrogen deficiency associated with supraphysio-logical plasmsa oestroadiol concentrations in women with oestradiol implants BMJ 1989; 299: 601-602.
70. Ganz PA. Greendale G, Kahn B, O’Leary JF. Are breast cancer survivors (BCS) willing to take hormone replacement therapy (HRT) (abstr 102)? Proceedings of the (32nd) Annual Meeting of the American Society of Clinical Oncology 1996; 15.
71. Ganz PA. Desmond K, Belin TR, Meyerowitz BE, Rowland JH. Predictors of sexual health in women after a breast cancer diagnosis. J Clin Oncol 1999; 17: 2371-2380.
72. Gapstur SM, Morrow M, Sellers TA. Hormone replacement therapy and risk of breast cancer with a favourable histology. JAMA 1999; 281: 2091-2097.
73. Ginsberg J, Prevlevic GM, Tibolone in postmenopausal women with a history ofbreast carcinoma. J Br Menopause Soc 1995; 1: 24-25.
74. Goldzieher JW. Pharmacology of contraceptive steroids: A brief review. Am J Obstet Gynecol 1989; 160: 1260-1264.
75. Gradishar WJ, Jordan VC. Clinical potential of new antioestrogens. J Clin Oncol 1997; 15: 840-852.
76. Grady D, Ernster V. Invited commentary: Does hormone replacement therapy cause breast cancer? Am J Epidemol 1991; 134: 1396-1400.
77. Grady D, Wenger NK, Herrington D, Khan S, Furberg C, Hunninghake D, Vittinghof E, Hulley S. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/Progestin Replacement Study. Ann Intern Med 2000; 132: 689-696.
78. Greendale GA, Reboussin BA, Sie A, Singh R, Olson LK, Gatewood O, Bassett LW, Wasilaukas C, Bush T, Barrett-Connor E for the Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Ann Intern Med 1999; 130: 262-269.
79. Grodstein F. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Joffe M, Rosner B, Fuchs C, Hankinson SE, Hunter DJ, Hennekens CH, Speizer FE. Postmenopausal hormone therapy and mortality. N Engl J Med 1997; 336: 1769-1775.
80. Hankinson SE, Willett WC, Manson JE, Colditz GA, Speigelman D, Barbieri RL, Speizer FE. Plasma sex steroid levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1998; 90: 1292-1299.
81. Hargreaves DF, Roberts SA, Howell A, Morton M. Effect of phyto-oestrogens on epithelial proliferation on the breast (abstr 084). Abstracts of the 6th Nottingham International Breast Cancer Conference, The Breast 1999; 8.
82. Harvey SC, DiPiro PJ, Meyer JE. Marked regression of a nonpalpable breast cancer after cessation ofHRT. Am J Roentgenol 1996; 167: 394-395.
83. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of oestrogen replacement therapy. Arch Intern Med 1991; 151: 75-78.
84. Hermon C, Beral V. Breast cancer mortality rates are levelling off or beginning to decline in many western countries: Analysis of time trends, age-cohort and age-period models of breast cancer mortality in 20 countries. Br J Cancer 1996; 73: 955-960.
85. Hofseth LJ, Raafat Am, Osuch JR, Pathak DR, Slomski CA, Haslam SZ. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 1999; 84: 4559-4565.
86. Hope S, Rees MCP. Why do British women start and stop hormone replacement therapy? J Br Menopause Soc 1995; 1: 26-27.
87. Horn Y, Walach N, Pavlotsky A, Barak F, Benz C. Randomised study comparing chemotherapy with and without estrogen priming in advanced breast cancer. Int J Oncol 1994; 4: 499-501.
88. Horowitz M, Wishart JM, Need AG, Morris HA, Nordin BE, Wishart JM. The effects of norethisterone on bone related biochemical variables and forearm bone mineral density in postmenopausal women. Clin Endocrinol 1993; 39: 649-655.
89. Howell A, Clarke RB, Anderson E. Oestrogen. Beatson and endocrine therapy. Endocr Rel Cancer 1997; 4: 371-380.
90. Howell R, Rose G. Failure of tibolone to control hypoestrogenic symptoms in premenopausal women undergoing hysterectomy and bilateral salpingoophorectomy. J Obstet Gynaecol 1997; 17: 578-579.
91. Hug V, Clark J, Johnson D. The results of modified use of chemotherapy for patients with metastatic breast cancer. Eur J Cancer 1994; 30A: 438-442.
92. Hulka BA, Stark AT. Breast cancer: Cause and prevention. Lancet 1995; 346: 883-887.
93. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E for the Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. Randomised trial of estrogen plus progestin for secondary heart disease in postmenopausal women. JAMA 1998; 280: 605-613.
94. Hunt K, Vessey M, McPherson K. Mortality in a cohort oflong-term users ofhormone replacement therapy: An updated analysis. Br J Obstet Gynaecol 1990; 97: 1080-1086.
95. Jeng M, Parker CJ, Jordan VC. Estrogenic potential in oral contraceptives to stimulate human breast cancer cell proliferation. Cancer Res 1992; 52: 6539-6546.
96. Jernstrom H, Frenander J, Ferno M, Olsson H. Hormone replacement therapy before breast cancer diagnosis significantly reduces the overall death rate compared with never-use among 984 breast cancer patients. Br J Cancer 1999; 80: 1453-1458.
97. Johannes E, Coelingh Bennick HJT, Engelen S, Kicovic P. Tibolone: dose-response analysis of effects in climacteric symptoms (abstr FC801.6). Acta Obstet et Gynaecologica Scand 1997; 76(Suppl 167): 5.
98. Jones C, Ingram D, Mattes E, Hahnel R. The effect of hormone replacement therapy on prognostic indices in women with breast cancer. Med J Aust 1994; 161: 106-110.
99. Jordan VC, Glusman JE, Eckert S, Lippman M, Powles T, Costa A, Morrow M, Norton L, Robert H. Raloxifene reduces incident primary breast cancer: integrated data from multicentre, double-blind, placebo-controlled, randomised trials in postmenopausal women (abstr 277). Br Cancer Res Treat 1998; 50.
100. Jung-Hoffman C, Fitzner M, Kuhl H. Oral contraceptives containing 20 or 30 micrograms ethinylestradiol and 150 micrograms desogestrel: Pharmacokinetics and pharmacodynamic properties. Horm Res 1991; 36: 238-246.
101. Kanis JA. Bisphosphonates and the rest-Non HRT agents in the treatment of osteoporosis. J Br Menopause Soc 1998; 4(Suppl 1): 9-11.
102. Kavanagh AM, Mitchell H, Giles GG, Hormone replacement therapy and accuracy of mammo-graphic screening. Lancet 2000; 355: 270-274.
103. Lane DM, Boatman KK, McConathy WJ. Serum lipids and apolipoprotiens in women with breast masses. Breast Cancer Res Treat 1995; 34: 161-169.
104. Laufer LR, Erlik Y, Meldrum DR, Judd HL. Effect of clonidine on hot flashes in postmenopausal women. Obstet Gynaecol 1982; 60: 583-586.
105. Lonning PE, Helle SI, Johannessen DC, Ekse D, Adlercreutz H. Influence of plasma oestrogen levels on the length of the disease-free interval in postmenopausal women with breast cancer. Br Cancer Res Treat 1996; 39: 335-341.
106. Loprinzi CL, Michalak JC, Quella SK, O’Fallen JR, Hatfield AK, Nelimark RA, Dose AM, Fischer T, Johnson C, Klatt NE, Bate WW, Rospond RM, Oesterling JE. Megestrol acetate for the prevention of hot flashes. N Engl J Med 1994; 331: 347-352.
107. Loprinzi CL, Alon-Ghazaleh S, Sloan JA, van Haelst-Pisani C, Hammer AM, Rowland KM, Law M, Windschitl HE, Kaur JS, Ellison N. Phase III randomised double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturiser in women with breast cancer. J Clin Oncol 1997; 15: 969-973.
108. Loprinzi CL, Kugler JW, Sloan J, Mailliard JA, LaVasseur B, Barton D, Novotny P, Dakhil S, Kardinal CG, Christensen BJ, Rodger K, Rummans TA. Venlafaxine alleviates hot flashes: A North Centre Cancer Treatment Group Trial (abstr 4). Proceedings of the (36th) Annual Meeting of the American Society of Clinical Oncology, 2000; 19.
109. Love RR, Cameron L, Connell BL, Levanthal H. Symptoms associated with tamoxifen treatment in postmenopausal women. Arch Intern Med 1991; 151: 1842-1847.
110. Magnusson C, Baron J, Correia N, Bergstrom R, Adami HO, Persson I. Breast cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int J Cancer 1999; 81: 339-344.
111. Markopoulous C, Berker U, Wilson P, Gazet JC, Coombes RC. Oestrogen receptor content of normal breast cells and breast carcinomas throughout the menstrual cycle. BMJ 1988; 296: 1349-1351.
112. Marsden J, Sacks, NPM, Baum M, A’Hern R, Whitehead MI. Are randomised trials of hormone replacement therapy in symptomatic breast cancer patients feasible? Fertil Steril 2000; 73: 292-299.
113. Matta WHM, Shaw, RW, Burford GD. Endocrinologic and clinical evaluation following a single administration of a gonadotrophin-releasing hormone agonist (Zoladex), in a depot formulation, to premenopausal women. Fertil Steril 1988; 49: 163-165.
114. Matthews PN, Millis RR, Hayward JL. Breast cancer in women who have taken contraceptive steroids. BMJ 1981; 282: 774-776.
115. Maudelonde T, Lavaud P, Salazar G, Laffargue F, Rochefort H. Progestin treatment depresses oestrogen receptor but not cathepsin D levels in needle aspirates of benign breast disease. Br Cancer Res Treat 1991; 19: 95-102.
116. Millard FC, Bliss JM, Chilvers CED, Gazet JC. Oral contraceptives and survival in breast cancer. Br J Cancer 1987; 56: 377-378.
117. Milner M, Sinnott M, Gasparao D, Kelly A, Carole BK, Harrison R. Climacteric symptoms, gonadotrophins, sex steroids and binding proteins with conjugated equine estrogen-progestin and tibolone over two years. Menopause: J N Am Menopause Soc 1996; 4: 208-213.
118. Mortimer JE, Boucher L, Baty J, Knapp DL, Ryan E, Rowland JH. Effect of tamoxifen on sexual functioning in patients with breast cancer. J Clin Oncol 1999; 17: 1488-1492.
119. Musgrove EA, Sutherland RL. Steroids, growth factors and cell cycle controls in breast cancer. Breast Cancer Res Treat 1991; 53: 305-331.
120. Nachtigall MJ, Smilen SW, Nacthigall RD, Nachtigall RH, Nachtigall LE. Incidence of breast cancer in a 22-year study of women receiving estrogen-progestin replacement therapy. Obstet Gynecol 1992; 80: 827-830.
121. O’Brien MER, Montes A, Powles TJ. Hormone replacement therapy as treatment of breast cancer- A phase II study of Org OD 14 (tibolone). Br J Cancer 1996; 73: 1086-1088.
122. Pandya KJ, Raubertas RF, Flynn PS, Hynes HE, Rosenbluth RJ, Kirshner JJ, Pierce HI, Dragalin V, Morrow GR. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flushes: A University of Rochester Cancer Centre Community Clinical Oncology Program Study. Ann Intern Med 2000; 132: 788-793.
123. Pasqualini JR, Kloosterboer HJ, Chetrite G. Action of tibolone and its metabolites (Org-4094, Org-20126) on the biosynthesis and metabolism of estradiol in human breast cancer cells (abstr P363). Breast Cancer Res Treat 1998; 50.
124. Persson I, Yuen J, Berqvist L, Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy-Long-term follow-up of a Swedish cohort. Int J Cancer 1996; 67: 327-332.
125. Persson I, Weiderpass E, Bergstrom R, Schairer C. Risks of breast cancer and endometrial cancer after estrogen and estrogen-progestin replacement therapy. Cancer Causes Control 1999; 10: 253-260.
126. Peters GN, Jones SE. Estrogen replacement therapy in breast cancer patients: A time for change (abstr 148). Proceedings of the (32nd) Annual Meeing of the American Society of Clinical Oncology 1996; 15.
127. Petrakis NL, Barnes S, King EB, Lowenstein J, Wiencke J, Lee MM, Miike R, Kirk M, Coward L. Stimulatory influence of soy protein isolate on breast secretion in pre- and postmenopausal women. Cancer Epidemiol Biomarkers Prev 1996; 5: 785-794.
128. Pike MC, Bernstein L, Spicer DV. Exogenous hormones and breast cancer. In: Niederhuber JE, ed. Current Therapy in Oncology. St Louis: Mosby, 1993, pp 292-303.
129. Pike MC, Peters RK, Cozen W, Probst-Hensch NM, Felix JC, Wan PC, et al. Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst 1997; 89: 1110-1116.
130. Pilote L, Hlatky MA. Attitudes of women toward hormone therapy and prevention of heart disease. Am Heart J 1995; 129: 1237-1238.
131. Plu-Bureau G, Le MG, Sitruk-Ware R, Thalabard JC, Mauvais-Jarvis P. Progestin use and decreased risk of breast cancer in a cohort study of premenopausal women with benign breast disease. Br J Cancer 1994; 70: 270-277.
132. Powles TP, Casey S, O’Brien M, Hickish T. Hormone replacement after breast cancer. Lancet 1993; 342: 60-61.
133. Powles TJ. Hickish T. Breast cancer response to HRT withdrawal. Lancet 1995; 345: 1442.
134. Powles TP, Hickish T, Kanis J, Tidy A, Ashley S. Effect of tamoxifen in bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996; 14: 78-84.
135. Powles TJ, Eeles R, Ashley S, Easton D, Chang J, Dowsett M, Tidy A, Viggers J, Davey J. Interim analysis of breast cancer in The Royal Marsden Hospital tamoxifen randomised chemopreven-tion trial. Lancet 1998; 352: 98-101.
136. Quella SK, Loprinzi CL, Barton D, Knost JA, Sloan J, Gerstner JB, LaVasseur B, Swan D, Krupp KRR, Miller KD, Novotny P. Evaluation of soy phytoestrogens for treatment of hot flashes in breast cancer survivors: an NCCTG trial (abstr 2285). Proceedings of the (35th) Annual Meeting of the American Society of Clinical Oncology 1999; 19.
137. Quella SK, Loprinzi CL, Sloan JA, Vaught NL, DeKrey WL, Fischer T, Finck G, Pierson N, Pisansky T. Long term use of megestrol acetate by cancer survivors for the treatment of hot flashes. Cancer 1998; 82: 1784-1788.
138. Rebbeck TR, Levin Am, Eisen A, Snyder C, Watson P, Cannon-Albright L, Isaacs C, Olopade O, Garber JE, Godwin AK, Daly MB, Narod SA, Neuhausen SL, Lynch HT, Weber BL. Breast cancer after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 1999; 91: 1475-1479.
139. Rees CMP, Brockie JA, Suffling K, O’Byrne K, Harris A, Clarke PJ. Megestrol acetate to treat vasomotor symptoms (abstr 233). Proceedings of the 8 th International Congress on the Menopause, Sydney, Australia 3rd-7th November 1996, Maturitas 1997; Suppl 1.
140. Rosen PP, Groschen S, Kinne DW, Norton L. Factors influencing prognosis in node-negative breast carcinoma: Analysis of 767 T1 N0 M0/T2 N0 M0 patients with long-term follow-up. J Clin Oncol 1992; 1: 2090-2100.
141. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy and breast cancer risk: Estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000; 92: 328-332.
142. Round Table Discussion 50, In: Sturdee D, ed. HRT and Thromboembolism. London: Royal Society of Medicine Press, 1997.
143. Rymer J, Chapman MG, Fogelman I, Wilson POG. A study of the effect of tibolone on the vagina in postmenopausal women. Maturitas 1994a; 18: 127-133.
144. Rymer JM, Chapman MG, Fogelman I. Effect of tibolone on postmenopausal bone loss. Osteoporosis International 1994b; 4: 314-319.
145. Rymer JM, Foley L, Chapman MG, Gibb DW, Fogelman I. Tibolone and the long-term effect on serum lipids (abstr FC076.2). Int J Obstet Gynaecol 1994c; 46(Suppl 2).
146. Sainsbury R. Timing of surgery and the ovarian cycle. Endocr Rel Cancer 1997; 4: 251-254.
147. Schaffer J, Fantl JA. Urogenital effects of the menopause. Ballières Clin Obstet Gynaecol 1996; 10: 401-417.
148. Schairer C, Byrne C, Keyl PM, Brinton LA, Sturgeon SR, Hoover RN. Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer. Cancer Causes Control 1994; 6: 416-424.
149. Schairer C, Gail M, Byrne C, Rosenberg PS, Sturgeon SR, Brinton LA, Hoover RN. Estrogen replacement therapy and breast cancer survival in a large screening study. J Natl Cancer Inst1999; 91: 264-270.
150. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000; 283: 485-491.
151. Schinzinger S. Ueber Carcinoma mammae (abstr). Centralbl Chir 1889; 16: 55-56.
152. Seeley T. Do women taking hormone replacement therapy have a higher uptake of screening mammograms? Maturitas 1994; 19: 93-96.
153. Sellers TA, Mink PJ, Cerhan JR, Zheng W, Anderson KE, Kushi LH, Folsom AR. The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer. Ann Intern Med 1997; 127: 973-980.
154. Sillero-Arenas M, Delgado-Rodriguez M, Rodigues-Canteras R, Bueno-Cavanillas A, Galvez Vargas R. Menopausal hormone replacement therapy and breast cancer: A meta-analysis. Obstet Gynecol 1992; 79: 286-294.
155. Speirs V, Parkes AT, Kerin MJ, Walton DS, Carleton PJ, Fox JN, Atkin SL. Coexpression of estrogen receptor: Poor prognostic factors in human breast cancer. Cancer Res 1999; 59: 525-528.
156. Spencer JD, Millis RR, Hayward JL. Contraceptive steroids and breast cancer. BMJ 1972; 2: 423-429.
157. Stallard S, Litherland JC, Cordiner CM, Dobson HM, George WD, Mallon EA, Hale D. Effect of hormone replacement therapy on the pathological stage of breast cancer: Population based, cross-sectional study. BMJ 2000; 320: 348-349.
158. Steinberg KK, Thacker SB, Smith JS, Stoup DF, Zack MM, Flanders WD, Berkelman RL. A metaanalysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991; 265: 1985-1990.
159. Stevenson JC, Lees B, Gardner R, Shaw RW. A comparison of the skeletal effects of goserelin and danazol in premenopausal women with endometriosis. Horm Res 1989; 32(Suppl 1): 161 -164.
160. Stoll BA. Hormone replacement therapy in women treated for breast cancer. Eur J Cancer Clin Oncol 1989; 25: 1909-1913.
161. Strickland DM, Gambrell RD, Butzin CA, Strickland K. The relationship between breast cancer survival and prior postmenopausal estrogen use. Obstet Gynecol 1992; 80: 400-404.
162. Sutton R, Buzdar AV, Hortobagyi GN. Pregnancy and offspring after adjuvant chemotherapy in breast cancer patients. Cancer 1990; 65: 847-850.
163. Taubes G. Epidemiology faces its limits. Science 1995; 269: 164-169.
164. Thijssen JH, Blankenstein MA. Endogenous oestrogens and androgens in normal and malignant endometrial and mammary tissues. Eur J Cancer Clin Oncol 1989; 25: 1953-1959.
165. Thomas HV, Key TJ, Allen D, Moore JW, Dowsett M, Fentiman IS, Wang DY. A prospective study ofendogenous serum hormone concentrations and breast cancer risk in post-menopausal women on the island of Guernsey. Br J Cancer 1997; 76: 401-405.
166. Toniolo PG, Levitz M, Zeleniuch-Jacquotte A, Banerjee S, Koenig KL, Shore RE, Strax P, Pasternack BS. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst 1995; 87: 190-197.
167. Valagassa P, Moliterni A, Zambetti M, Bonadonna G. Long-term sequelae from adjuvant chemotherapy. Recent Results Cancer Res 1993; 127: 247-255.
168. Vassilopoulou-Sellin R, Klein MJ. Estrogen replacement therapy after treatment for localised breast carcinoma, patients responses and opinions. Cancer 1996; 78: 1043-1048.
169. Vassilopoulou-Sellin R, Theriault R, Klein MJ. Estrogen replacement therapy in women with prior diagnosis and treatment for breast cancer (abstr 50). Proceedings of the (32nd) Annual Meeing of the American Society of Clinical Oncology 1996; 15.
170. Vassilopoulou-Sellin R, Theriault RL. Randomised prospective trial of estrogen-replacement therapy in women with a history of breast cancer. Monogr Natl Cancer Inst 1994; 16: 153-159.
171. Vassilopoulou-Sellin R, Zolinski C. Estrogen-replacement therapy in women with breast cancer: a survey of patient attitudes. Am J Med Sci 1992; 304: 145-149.
172. Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C, Rotmensz N, Boyle P. Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomised trial among hysterectomised women. Lancet 1998; 352: 93-97.
173. Vessey M, Baron J, Doll R, McPherson K, Yeates D. Oral contraceptives and breast cancer. Final report of an epidemiological study. Br J Cancer 1983; 47: 455-462.
174. von Scholtz E, Johansson H, Wilking N, Rutqvist LE. Influence of prior and subsequent pregnancy on breast cancer prognosis. J Clin Oncol 1995; 13: 430-434.
175. Whitehead MI, Godfree V. Types of HRT available. In: Whitehead MI, Godfree V, eds, HRT: Your Questions Answered, Edinburgh: Churchill Livingstone, 1992, pp 93-122.
176. Wile AG, Opfell RW, Margileth DA. Hormone replacement therapy in previously treated breast cancer patients. Am J Surg 1993; 165: 372-375.
177. Williamson K, Robertson JF, Ellis IO, Elston CW, Nicholson RI, Blamey RW. Effect of LHRH agonist, Zoladex, on ovarian histology. Br J Surg 1988; 75: 595-596.
178. Willis DB. Calle EE, Miracle-McMahill HL, Heath CW. Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States. Cancer Causes Control 1996; 7: 449-457.
179. Wren BG. Hormonal replacement therapy and breast cancer. Eur J Menopause 1995; 2: 13-21.
180. Yasamura T, Akami T, Mitsou M, Oka T, Naitoh K, Yasamuara T, Honjyo H, Okada H. The effect of adjuvant therapy with or without tamoxifen on the endocrine function of patients with breast cancer. Jpn J Surg 1990; 20: 369-375.
181. Zahasky KM, Loprinzi CL, Sloan J, Novotny PJ, Quella SK. Detailed prospective data regarding tamoxifen-induced hot flashes (abstr 2283). Proceedings of the (35th) Annual Meeting of the American Society of Clinical Oncology 1999; 19.